Biography
Matthew Gubens, MD, MS, FASCO is Professor of Medicine at UCSF, where he practices as a thoracic medical oncologist and serves as Medical Director of Thoracic Medical Oncology. He is also Chair of the UCSF Cancer Center Protocol Review and Monitoring Committee which oversees scientific review of clinical cancer research at the institution. Dr. Gubens is Immediate Past Chair of the ASCO Evidence Based Medicine Committee which oversees the ASCO Guidelines program, and he also co-chairs the ASCO Thoracic Guideline Advisory Group. Dr. Gubens serves on the National Comprehensive Cancer Network panels for non-small cell lung cancer, mesothelioma, and thymic malignancies. He is on the Board of Directors of the Association of Northern California Oncologists. Dr Gubens completed his BA at Yale, his MS at the Harvard School of Public Health, and his MD at Stanford, and trained in internal medicine residency at UCSF and then medical oncology at Stanford.
Education
| Institution | Degree | Dept or School | End Date |
|---|---|---|---|
| Stanford University | Fellowship | School of Medicine - Medical Oncology | 2011 |
| University of California, San Francisco | Residency | School of Medicine - Internal Medicine | 2008 |
| Stanford University | M.D. | School of Medicine | 2005 |
| Harvard School of Public Health | M.S. | Health Policy and Management | 2000 |
| Yale University | B.A. | Ethics, Politics and Economics | 1997 |
Board Certifications
American Board of Internal Medicine, Internal Medicine
Clinical Expertise
Bronchioloalveolar Carcinoma (BAC)
Chest Wall Tumors
Lung Carcinoid Tumors
Lung Metastases
Malignant Mesothelioma
Mediastinal Tumors
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Thymoma & Thymic Carcinoma
Program Affiliations
Department of Medicine, Division of Hematology Oncology
Thoracic Oncology Program
UCSF Helen Diller Family Comprehensive Cancer Center
Research Interests
Thymoma & Thymic Carcinoma
Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
- Non-Small Cell Lung Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.| |
PubMed
- NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 7.2025.| |
PubMed
- Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer.| |
PubMed
- Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.| |
PubMed
- Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.| |
PubMed
- Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events.| |
PubMed
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.| |
PubMed
- Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights.| |
PubMed
- American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy.| |
PubMed
- Appropriate Use Criteria (AUC) for the Management of Non-Small Cell Lung Cancer in a Central/Ultra-Central Location: Guidelines from the American Radium Society.| |
PubMed